बिहारशरीफ, मई 8 -- उद्योगपति युवाओं को प्रशिक्षण व रोजगार देने में निभाएं सक्रिय भूमिका: निदेशक युवाओं को रोजगार से जोड़ने के लिए सरकार चला रहीं कई योजनाएं हरदेव भवन में रोजगार व कौशल विकास पर जागरूकता... Read More
Hyderabad, May 8 -- Special Intensive Revision (SIR) mapping has picked pace in Hyderabad, with the highest percentage recorded in the Bahadurpura Assembly constituency. In just two weeks, the percen... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Mon... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in ... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ef... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascimin... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with c... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy ve... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and... Read More
Singapore, May 8 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adju... Read More